FASLG and melanoma: Also consistent with our results with SkOV3-CD19, we show that A375-CD19 melanoma cells are sensitive to combined FasL and GZMB inhibition, since it is already known that Fas expression of A375 is comparable to SkOV3 (Fig. 7E, F) [12].